Participant receives both curcumin and prednisolone. Curcumin for 11 days, prednisolone for 10 days. Curcumin: 2 tablets (each contains 100 mg curcumin) twice daily. Prednisolon: 50 mg (capsule) every morning

Participant receives prednisolone and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon: 50 mg (capsule) every morning

Participant receives prednisolone.placebo and curcumin-placebo. Curcumin-placebo for 11 days, prednisolone-placebo for 10 days. Curcumin-placebo: 2 tablets twice daily. Prednisolon-placebo: One capsule every morning.

Insulin Resistance

Non-Alcoholic Fatty Liver Disease

Curcumin is given together with prednisolone

Curcumin Liposome

Prednisolone is given together with curcumin-placebo

Prednisolone

Prednisolone-placebo is given together with curcumin-placebo

Placebos

Center for Clinical Metabolic Research

The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance

The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance in Overweight and Obese Participants

homeostatic model assessment of insulin resistance is calculated before and after intervention

Measured by MR spectroscopy of the liver (unit: %)

Estimated by collecting urin for 4-5 hours, measuring volume of urine and urea concentration

Feces sample before and after intervention

subcutaneously, interstitial measurement (concentration of glucose) every 15 minutes in the intervention period

icare 100 tonometer measurement (unit: mmHg)

measured by bioimpedance (units: kg and %)

MR-spectroscopy measurement (unit: cm3 at L3-level, 1 cm thick slice)

visual analogue scale evaluation (no visible numbers/points, just a clear line)

Evaluated by calculating ingested meal at ad libitum meal at test days (unit: grams and calories)

Visual analogue scale (no points/number visible, just a clear line)

Pernille Høgh Hellmann

Medical Doctor, primary investigator

University Hospital, Gentofte, Copenhagen

After study day 1, participants are randomized (1:1:1) to one of three treatments: 1) Prednisolon and Curcumin, 2) Prednisolon and placebo or 3) Placebo and placebo.

To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.

ranibizumab: 0.5mg ranibizumab given intravitreally as needed after initial treatment

Ranibizumab

Sex: Female, Male

The mean change in best corrected Snellen visual acuity at 6 months in NAION patients treated as needed with ranibizumab.

Change in Visual Acuity

Overall Study

Dr. Naresh Mandava, M.D.

Nonarteritic Anterior Ischemic Optic Neuropathy

All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.

ranibizumab

Rocky Mountain Lions Eye Institute

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION)

University of Colorado, Denver

Genentech, Inc.

Mecamylamine-Smoker

Mecamylamine-Non-Smoker

Placebo-Smoker

Placebo- Non-Smoker

Total

Race/Ethnicity, Customized

Veteran Status

Data were calculated as number of heavy drinking days (heavy drinking days is defined as 5 drinks on a single occasion for men and 4 for women) average during 90 days of treatment.

Mecamylamine- Smokers

Mecamylamine- Non-Smoker

Percent Heavy Drinking Days During Active Treatment Phase

The OCDS is a 14-item (rated 0-4), self-administered questionnaire for characterizing and quantifying the obsessive and compulsive cognitive aspects of craving and heavy (alcoholic) drinking, such as drinking-related thought, urges to drink, and the ability to resist those thoughts and urges. A higher total score indicates higher craving and ranges from 0-48.

Mecamylamine

Placebo

Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)

Questionnaire of smoking urges (QSU). It has 32 questions that range from 1 to 7, there are 8 questions per sub-scale. The total range is 32 to 224. Each sub-scale ranges from 8- 56, with a higher score indicating higher craving.

Self-report Weekly Smoking Craving

self-report from only the smoking population for cigarettes per day

glaucoma/nikotin

The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Nicotinic Receptor Augmentation of SSRI Antidepressants

A legteljesebb gyógynövény-adatbázis, amelyet a tudomány támogat